JG
TPST icon

Jefferies Group’s Tempest Therapeutics TPST Stock Holding History

Jefferies Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36
Closed -$12 – 1544
2020
Q2 		$12 Hold
36
– – ﹤0.01% 1194
2020
Q1 		$37K Buy
+36
New +$52.5K ﹤0.01% 1902

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Jefferies Group's TPST Position: Q3 2020 in Review

Jefferies Group sold out of Tempest Therapeutics (TPST) in Q3 2020, closing a stake of 36 shares — an estimated $12 sold.

Jefferies Group first reported a position in TPST in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q1 2020. 42 funds tracked by Wall St. Rank hold TPST as of Q3 2020.

  • Jefferies Group reported no remaining Tempest Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 36 Tempest Therapeutics shares in Q3 2020, an estimated $12.
  • Jefferies Group first reported a position in Tempest Therapeutics in Q1 2020 and held it in 2 quarters.
  • Jefferies Group's Tempest Therapeutics position peaked at $15K in Q1 2020.
  • 42 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.